Results 321 to 330 of about 63,359 (335)

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.

Journal of Clinical Oncology, 2022
7018 Background: Isocitrate dehydrogenase-1 mutations ( IDH1+) result in production of the oncometabolite 2-hydroxyglutarate, arrested differentiation, and increased dependence on the anti-apoptotic protein BCL-2, enhancing susceptibility to the BCL-2 ...
Curtis A. Lachowiez, Jacqueline S. Garcia, G. Borthakur, S. Loghavi, Z. Zeng, G. Tippett, T. Kadia, L. Masarova, M. Yilmaz, A. Maiti, P. Bose, Koichi Takahashi, E. Jabbour, F. Ravandi, N. Daver, G. Garcia-Manero, P. Vyas, H. Kantarjian, M. Konopleva, C. Dinardo   +19 more
semanticscholar   +1 more source

In Situ Sprayed Starvation/Chemodynamic Therapeutic Gel for Post‐Surgical Treatment of IDH1 (R132H) Glioma

Advances in Materials, 2021
Complete resection of isocitrate dehydrogenase 1 (IDH1) (R132H) glioma is unfeasible and the classic post‐surgical chemo/radiotherapy suffers from high recurrence and low survival rate.
Chunying Li, Yilin Wan, Yifan Zhang, Lian-Hua Fu, N. Blum, Run Cui, Boda Wu, Rui Zheng, Jing Lin, Zhiming Li, Peng Huang   +10 more
semanticscholar   +1 more source

Abstract 4620: Wild-type IDH1: A molecular target in IDH1 mutant cancers

Cancer Research, 2014
Abstract Neomorphic mutations targeting R132 of the TCA cycle enzyme, IDH1, have been identified in multiple cancer types and lead to a build up of (R)-2-hydroxyglutarate ((R)-2HG). Several mechanisms have been proposed to account for mutant-IDH1-mediated transformation: due to its structure similarity with alpha-ketoglutarate (α-KG), (R)
Paul Russell, Tom Henley, Jonathan D. Moore, Christine Schofield, Julie A Wickenden, Mark Stockdale, Dan Gitterman, Jane Elliott, Chris Torrance, Amy Smith   +9 more
openaire   +2 more sources

IDH1/2 mutation detection in gliomas

Brain Tumor Pathology, 2014
Somatic mutations of isocitrate dehydrogenase 1 and 2 (IDH1/2) are strongly associated with pathological subtypes, genetic profiles, and clinical features in gliomas. The IDH1/2 status is currently regarded as one of the most important molecular markers in gliomas and should be assessed accurately and robustly.
Naoya Hashimoto, Hideyuki Arita, Yoshitaka Narita, Akihiko Yoshida, Toshiki Yoshimine, Koichi Ichimura   +5 more
openaire   +3 more sources

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor

European Journal of Medicinal Chemistry, 2023
Through a structure-based irreversible drug design approach, we have discovered a highly potent IDH1-mutant inhibitor compound 16 (IHMT-IDH1-053) (IC50 = 4.7 nM), which displays high selectivity against IDH1 mutants over IDH1 wt and IDH2 wt/mutants.
Qianmao Liang, Beilei Wang, Fengming Zou, Gongrui Guo, Wenliang Wang, Wei Wang, Qingwang Liu, Lijuan Shen, Chen Hu, Wenchao Wang, Aoli Wang, Tao Huang, Yuying He, Ruixiang Xia, Jian Ge, Jing Liu, Qingsong Liu   +16 more
openaire   +2 more sources

Final results from ClarIDHy, a global, phase III, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

, 2021
266Background: CCA is a rare cancer for which there are limited effective therapies. IDH1 mutations occur in ~20% of intrahepatic CCAs, resulting in production of the oncometabolite D-2-hydroxyglut...
A. Zhu, T. Macarulla, M. Javle, R. Kelley, S. Lubner, J. Adeva, J. Cleary, D. Catenacci, M. Borad, J. Bridgewater, W. Harris, A. Murphy, D. Oh, J. Whisenant, Bin Wu, Liewen Jiang, C. Gliser, S. Pandya, J. Valle, G. Abou-Alfa   +19 more
semanticscholar   +1 more source

Targeting IDH1/IDH2 mutations in gliomas

Current Opinion in Neurology, 2022
Purpose of review Somatic point mutations in the metabolic enzyme isocitrate dehydrogenase (IDH) are a defining feature of the majority of WHO grade 2–3 diffuse glioma and the most powerful positive prognostic factor for survival in gliomas. The purpose is to review experimental therapeutic approaches targeting IDH mutations in
openaire   +2 more sources

IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis

Virchows Archiv, 2019
Mosaic somatic mutations in the isocitrate dehydrogenase 1/2 (IDH1/2) genes have been identified in most enchondromas by targeted mutation analysis. Next-generation sequencing (NGS), that may detect even low-level mosaic mutation rates, has not previously been applied to enchondromas.
Essia Saiji, Fabienne Gumy Pause, Pierre Lascombes, Christelle Cerato Biderbost, Nathalie Lin Marq, Margaret Berczy, Laura Merlini, Anne-Laure Rougemont   +7 more
openaire   +4 more sources

Metabolism of glioma and IDH1/IDH2 mutations

Revue Neurologique, 2011
Many known oncogenic signaling pathways involved in gliomagenesis have strong consequences on tumor cell metabolism, and promote the switch from oxidative phosphorylation to aerobic glycolysis, for ATP generation. However, the interest on metabolism has been recently renewed by the discovery of recurrent mutation of IDH1 genes by systematic sequencing ...
Marta Rossetto, Pietro Ciccarino, Blandine Boisselier, Marianne Labussière, Marc Sanson   +4 more
openaire   +3 more sources

Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo

Acta Neuropathologica, 2017
Mutations in codon 132 of isocitrate dehydrogenase (IDH) 1 are frequent in diffuse glioma, acute myeloid leukemia, chondrosarcoma and intrahepatic cholangiocarcinoma. These mutations result in a neomorphic enzyme specificity which leads to a dramatic increase of intracellular D-2-hydroxyglutarate (2-HG) in tumor cells. Therefore, mutant IDH1 protein is
Christel Herold-Mende, Ann Christin Beck, Viktoria Eichwald, Stefan Kaulfuss, Luisella Toschi, Andrea Haegebart, Holger Hess-Stumpp, Jessica Eisel, Michael Platten, Michael Platten, Manfred Jugold, Hartmut Rehwinkel, Sonja Krausert, Andreas Unterberg, Judith Guenther, Wolfgang Wick, Wolfgang Wick, Stefan Pusch, Stefan Pusch, Roman C. Hillig, Jörg Balss, Jörg Balss, Daniel Schrimpf, Daniel Schrimpf, Martina Ott, Martina Ott, Markus Bauser, Roland Neuhaus, Felix Sahm, Felix Sahm, Andreas von Deimling, Andreas von Deimling, Katja Zimmermann, Viktoria Fischer, Viktoria Fischer, David Capper, David Capper, Olaf Panknin   +37 more
openaire   +3 more sources